Trials / Completed
CompletedNCT03130478
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole Long-acting Injection in the Spanish Clinical Practice: a Retrospective, Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 119 (actual)
- Sponsor
- Otsuka Pharmaceutical Europe Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated on AOM treatment during an schizophrenia-related hospitalisation at least 6 months before data collection and in a real clinical practice setting.
Detailed description
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated on AOM treatment during an schizophrenia-related hospitalisation at least 6 months before data collection and in a real clinical practice setting. Data from each patient will be collected after informed consent is obtained (if possible), and will include retrospective information mainly from the index date (start of AOM treatment, baseline timepoint) until the last information available in the patient file at the time of data collection (minimum of 6 months after the index date). Data will be retrospectively collected from all visits occurring as per clinical practice (usually once-monthly).
Conditions
Timeline
- Start date
- 2017-07-18
- Primary completion
- 2018-07-30
- Completion
- 2018-07-30
- First posted
- 2017-04-26
- Last updated
- 2018-08-21
Locations
15 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT03130478. Inclusion in this directory is not an endorsement.